GlassScriptPhysician profile
Robert J Barrucco
NPI 1346408747
$4,574.85
in general payments reported to CMS, 2019-2025
22 companies · $733 in 2025
The $733 reported for 2025 was more than what a typical Cardiovascular Disease provider received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $636 · 2020: $381 · 2021: $1,008 · 2022: $249 · 2023: $775 · 2024: $793 · 2025: $733.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,279 · Education: $21.70.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,279.17 |
| Education | $21.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Impulse Dynamics (USA) INC. | $766.49 | 2019-2025 | Optimizer |
| Boston Scientific Corporation | $586.06 | 2019-2025 | Watchman Flx, Lux-Dx Insertable Cardiac Monitor |
| Janssen Pharmaceuticals, INC | $464.30 | 2019-2024 | Xarelto |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $432.23 | 2019-2025 | Lifevest |
| Kestra Medical Technology Services, INC. | $388.58 | 2023-2025 | Assure Wcd |
| Novartis Pharmaceuticals Corporation | $364.48 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $216.71 | 2023-2025 | Camzyos |
| Astrazeneca Pharmaceuticals LP | $211.84 | 2019-2023 | Farxiga |
| Amgen INC. | $188.71 | 2020-2025 | Repatha, Repatha |
| Abbott Laboratories | $170.50 | 2019-2024 | Thoratec Heartmate 3 Lvas Implant Kit |
| Boehringer Ingelheim Pharmaceuticals, INC. | $160.13 | 2022-2025 | Jardiance |
| Irhythm Technologies, INC. | $143.42 | 2023 | Zio Xt Patch |
| Atricure, INC. | $81.72 | 2022 | |
| Merck Sharp & Dohme LLC | $77.22 | 2022-2023 | Verquvo |
| Edwards Lifesciences Corporation | $74.22 | 2019-2023 | Edwards Sapien 3 Transcatheter Heart Valve (Thv), Edwards Sapien 3 Ultra Transcatheter Heart Valve |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $69.94 | 2019-2022 | |
| Scpharmaceuticals INC. | $61.06 | 2024-2025 | |
| Pfizer INC. | $38.16 | 2019-2023 | |
| Bayer Healthcare Pharmaceuticals INC. | $33.57 | 2025 | |
| Biotronik INC. | $20.34 | 2020 | |
| Regeneron Healthcare Solutions, INC. | $13.73 | 2019 | |
| Astellas Pharma US INC | $11.44 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Robert Barrucco listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.